Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer

NCT00046800 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00046800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2002
Completion date
March 31, 2003
Enrollment
80
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms